182 related articles for article (PubMed ID: 23135868)
1. Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
Suzuki H; Okada K; Abe M; Maruyama N; Yoshida Y; Baba S; Takashima H; Soma M
Clin Exp Nephrol; 2013 Jun; 17(3):386-95. PubMed ID: 23135868
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
Giles TD; Alessi T; Purkayastha D; Zappe D
J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
[TBL] [Abstract][Full Text] [Related]
10. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren/valsartan (Valturna) for hypertension.
Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
[No Abstract] [Full Text] [Related]
13. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
14. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Yarows SA
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
Bakris GL; Oparil S; Purkayastha D; Yadao AM; Alessi T; Sowers JR
J Clin Hypertens (Greenwich); 2013 Feb; 15(2):92-100. PubMed ID: 23339726
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.
Flack JM; Yadao AM; Purkayastha D; Samuel R; White WB
J Am Soc Hypertens; 2012; 6(2):142-51. PubMed ID: 22321963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
